Doxycycline after sex: the prophylaxis that divides doctors - MST

Guido Donati * 02 Nov 2026



A single dose of doxycycline taken within 72 hours of condomless sex cut syphilis, chlamydia and gonorrhoea by about two thirds among men who have sex with men and transgender women followed in San Francisco and Seattle. In the United States the CDC has recommended it since 2024 and the WHO has allowed it, with conditions, since July 2026, while the ECDC does not recommend it as a population-level measure. Against gonorrhoea the effect is already wearing thin, because more than half of Europe's gonococci resist tetracyclines. What remains unknown is how much resistance each prevented infection costs.

 

 

Relative reduction in the risk of gonorrhoea, chlamydia and syphilis with doxycycline taken after sex in the DoxyPEP trial (San Francisco and Seattle), in the two groups of participants: people using PrEP against HIV and people living with HIV. For syphilis among people with HIV the cases were few and the reduction may be due to chance. Chart produced by ScienceOnline from data in Anne F. Luetkemeyer and colleagues, New England Journal of Medicine, 2023.


SEXUALLY TRANSMITTED INFECTIONS · 6


On 6 June 2024 the Centers for Disease Control and Prevention (CDC), the federal health agency of the United States, published its guidelines on doxy-PEP. Laura Bachmann, Leandro Mena and their co-authors ask doctors to offer a doxycycline prescription to a specific group. It comprises men who have sex with men and transgender women with at least one case of syphilis, chlamydia or gonorrhoea in the past year. The dose is 200 milligrams, taken as soon as possible and no later than 72 hours after oral, vaginal or anal sex. It is post-exposure prophylaxis, a medicine taken after a possible infection, hence the acronym PEP.
Nineteen months later, in January 2026, the European Centre for Disease Prevention and Control (ECDC) in Stockholm took a far more cautious line. Its document does not recommend doxy-PEP as a public health intervention aimed at whole groups and leaves the decision to doctors, one patient at a time. The two agencies were looking at the same clinical trials. An antibiotic pill after sex sharply reduces infections, but at what price for antibiotic resistance? And why is Europe more cautious than the United States?
It all starts with a trial called DoxyPEP. Anne Luetkemeyer, Connie Celum and colleagues published it in April 2023 in the New England Journal of Medicine. At clinics in San Francisco and Seattle they enrolled 501 men who have sex with men and transgender women. All had had a bacterial sexually transmitted infection in the previous year. Of these, 327 were taking PrEP, pre-exposure prophylaxis against HIV, while the other 174 were living with HIV. A random draw gave two participants in three doxycycline to take after condomless sex. The remaining third continued with standard care, and everyone was tested every three months.


Among PrEP users an infection turned up at 10.7 per cent of quarterly visits with doxycycline and at 31.9 per cent without it. The risk fell by about two thirds, and the same happened among people living with HIV. The protection varied from one germ to another, though. In the PrEP group the risk of chlamydia dropped by 88 per cent and that of syphilis by 87. Gonorrhoea stopped at 55. Syphilis cases were few and the margin of uncertainty remains wide. The CDC calculates that treating fewer than five people prevents one visit with a new infection. The authors attributed five grade 3 adverse effects to the drug, severe but not life-threatening, and no serious adverse events.


In France Jean-Michel Molina and the ANRS 174 DOXYVAC study group reached a similar result. Between January 2021 and September 2022, at ten Paris hospitals, they randomised 556 HIV-negative men using PrEP. The trial tested two things at once. Alongside doxycycline came the meningococcal B vaccine, 4CMenB, which it was hoped might also protect against gonorrhoea, since the two bacteria belong to the same genus, Neisseria. With doxycycline, chlamydia and syphilis fell to 8.8 cases per 100 person-years, that is per hundred people followed for a year, against 53.2 without it. The vaccine brought gonorrhoea down from 77.1 to 58.3, a difference that stays within the bounds of chance. The paper appeared in The Lancet Infectious Diseases in October 2024.
The third trial dampened the enthusiasm. In Kisumu, Kenya, the team led by Jenell Stewart, Elizabeth Bukusi and Jared Baeten enrolled 449 women aged 18 to 30, all on PrEP. In the New England Journal of Medicine, in December 2023, they reported a risk reduction of just 12 per cent, a result consistent with no effect at all. Nine in ten of the women's diaries recorded the pill taken after at least 80 per cent of sexual encounters. Yet in the hair of fifty participants chosen at random, doxycycline was found in only 29 per cent of samples. All sixteen gonococci tested at enrolment also carried the tetM gene, which makes the bacterium highly resistant to tetracyclines, the antibiotic family doxycycline belongs to. The authors put the failure down mainly to how little of the drug was actually taken, and partly to that resistance.


Resistance is precisely what separates Europe from the United States. According to the ECDC document, coordinated by Otilia Mårdh, 58.4 per cent of the 3,014 gonococci collected in 2023 by the European surveillance network Euro-GASP were resistant to tetracyclines. In seven countries, the year before, the share topped 70 per cent. High-level resistance, the kind carried by the tetM gene, affected 11.9 per cent of strains in 2023. With figures like these, the agency concludes, the prophylaxis is unlikely to reduce gonorrhoea in most EU countries and could rapidly select resistant strains. That is why the ECDC sets syphilis prevention as the main aim, in people at highest risk.


In the United States the erosion is starting to be measured. Matan Yechezkel, Joseph Lewnard and colleagues followed 26,582 members of Kaiser Permanente in southern California from 2023 to June 2025. The work was released as a preprint in January 2026, before review by other experts. Against chlamydia and syphilis, doxycycline kept an estimated effectiveness of around 67 and 61 per cent. Against gonorrhoea, effectiveness slid from 42 per cent before the state adopted the prophylaxis to below zero in the first half of 2025. Over the same period the share of gonococci carrying tetM was rising. In San Francisco, Hyman Scott and Susan Buchbinder counted 1,209 PrEP users at the San Francisco AIDS Foundation's Magnet clinic who had started doxy-PEP. In their report, published in December 2025 in Sexually Transmitted Infections, infections fall by 58 per cent. Chlamydia and syphilis drop, while gonorrhoea barely moves.


The bill is not limited to the germs of venereal disease. In the DoxyPEP trial, the CDC reports, those taking doxycycline less often carried Staphylococcus aureus in the nose. It is a bacterium many people host without harm and that sometimes causes skin and bloodstream infections. Among carriers, however, strains resistant to tetracyclines became more common. The ECDC document also cites an analysis by the same Californian group of the gut microbiome, the community of bacteria living in the intestine. Tetracycline resistance genes increased, while the overall make-up of the bacteria changed little. In the French trial, the European agency adds, some gonococci from the treated group carried both the tetM gene and a mosaic form of the penA gene. The latter weakens cephalosporins, the family that includes ceftriaxone, and points to resistances that can pile up in the same bacterium.


The World Health Organization has taken a middle road. On 14 July 2026, in Geneva, it published its first guideline on doxy-PEP, with a conditional recommendation, one that depends on context, and evidence judged to be of moderate certainty. The prophylaxis may be offered to men who have sex with men and to transgender women, giving priority to those with a recent infection, especially syphilis. On the effects on resistance, the WHO rates the certainty as low or very low and calls for monitoring. For women and other groups it does not, for now, recommend it.
In Italy the prophylaxis is already in circulation. Between October 2024 and March 2025 Roberto Rossotti, Silvia Nozza and other members of the Italian Society of Infectious and Tropical Diseases (SIMIT) surveyed 132 infectious disease specialists. In their paper, published in 2026 in the same journal as Scott's, 44 per cent say they prescribe it, mostly in sexual health and PrEP clinics. Resistance tops the list of concerns for 96.2 per cent, and 46.2 per cent report informal use without medical supervision.


For now the balance sheet has two columns. On one side are the chlamydia and syphilis infections prevented, down by 60 per cent or more in trials and clinics. On the other is tetracycline resistance, which already affects most gonococci in Europe and in California is rising alongside the prophylaxis. The gap between the two sides of the Atlantic stems from this, because Europe starts from more resistant gonococci and aims at syphilis alone. Published studies follow participants for one or two years. How much the second column weighs in the nose and gut bacteria of people who take the pill for many years has yet to be measured.




References
Anne F. Luetkemeyer, Deborah Donnell, Julia C. Dombrowski, Stephanie Cohen, Cole Grabow, Clare E. Brown, Cheryl Malinski, Rodney Perkins, Melody Nasser, Carolina Lopez, Eric Vittinghoff, Susan P. Buchbinder, Hyman Scott, Edwin D. Charlebois, Diane V. Havlir, Olusegun O. Soge, Connie Celum and the DoxyPEP Study Team, ‘Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections’, New England Journal of Medicine, 388, 14, 1296–1306, 2023. https://doi.org/10.1056/NEJMoa2211934
Jean-Michel Molina, Beatrice Bercot, Lambert Assoumou, Emma Rubenstein, Michele Algarte-Genin, Gilles Pialoux, Christine Katlama, Laure Surgers, Cécile Bébéar, Nicolas Dupin et al., for the ANRS 174 DOXYVAC study group, ‘Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design’, The Lancet Infectious Diseases, 24, 10, 1093–1104, 2024. https://doi.org/10.1016/S1473-3099(24)00236-6
Jenell Stewart, Kevin Oware, Deborah Donnell, Lauren R. Violette, Josephine Odoyo, Olusegun O. Soge, Caitlin W. Scoville, Victor Omollo, Felix O. Mogaka, Fredericka A. Sesay, R. Scott McClelland, Matthew Spinelli, Monica Gandhi, Elizabeth A. Bukusi, Jared M. Baeten and the dPEP Kenya Study Team, ‘Doxycycline Prophylaxis to Prevent Sexually Transmitted Infections in Women’, New England Journal of Medicine, 389, 25, 2331–2340, 2023. https://doi.org/10.1056/NEJMoa2304007
Laura H. Bachmann, Lindley A. Barbee, Philip Chan, Hilary Reno, Kimberly A. Workowski, Karen Hoover, Jonathan Mermin, Leandro Mena, ‘CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024’, MMWR Recommendations and Reports, 73, 2, 1–8, 2024. https://doi.org/10.15585/mmwr.rr7302a1
European Centre for Disease Prevention and Control (coordinated by Otilia Mårdh), ‘Public health considerations on the use of doxycycline for post-exposure prophylaxis for bacterial sexually transmitted infections in the EU/EEA’, Stockholm, ECDC, 2026. https://doi.org/10.2900/3981588
World Health Organization, ‘Guideline on doxycycline post-exposure prophylaxis for sexually transmitted infections among men who have sex with men and transgender women’, Geneva, WHO, 2026, ISBN 978-92-4-012411-0. https://www.who.int/publications/i/item/9789240124110
Matan Yechezkel, David Helekal, Banshri Kapadia, Vennis Hong, Magdalena E. Pomichowski, Iris Anne C. Reyes, Gregg S. Davis, Nicola F. Müller, Yonatan H. Grad, Sara Y. Tartof, Joseph A. Lewnard, ‘Rapid loss of doxycycline effectiveness against gonorrhea after implementation of post-exposure prophylaxis in southern California: an observational study’, medRxiv (preprint), 2026. https://doi.org/10.64898/2026.01.07.26343623
Hyman M. Scott, Jorge Roman, Matthew Spinelli, Jason Bena, Thiago Torres, David Glidden, Susan Buchbinder, ‘Sexually transmitted infections after implementation of doxycycline postexposure prophylaxis’, Sexually Transmitted Infections, 102, 322–324, 2026. https://doi.org/10.1136/sextrans-2025-056674
Roberto Rossotti, Angelo Roberto Raccagni, Federico D'Amico, Emanuele Nicastri, Giovanni Mazzola, Antonio Cascio, Marco Falcone, Ivan Gentile, Andrea Giacomelli, Cristina Mussini, Roberto Parrella, Silvia Nozza, ‘Attitudes and prescribing practices on doxycycline postexposure prophylaxis (DoxyPEP) among Italian infectious diseases physicians: findings from a National SIMIT Survey’, Sexually Transmitted Infections, 102, 2, 103, 2026. https://sti.bmj.com/content/102/2/103


Previous articles on ScienceOnline
Guido Donati, ‘Gonorrhoea: ceftriaxone holds. In Bologna, the first strain that resists it’ (title to be checked), ScienceOnline, 26 October 2026 
Guido Donati, ‘Hepatitis C in France: among people who use drugs, active infection halves in ten years’ , ScienceOnline, 16 October 2026 
Guido Donati, ‘HPV: a single dose holds up against two. In Italy only half of twelve-year-old girls have completed the vaccine’ , ScienceOnline, 15 October 2026 
Guido Donati, ‘Congenital syphilis: cases double in Europe, Italy counts seven’ (title to be checked), ScienceOnline, 17 September 2026 


*Board Member, SRSN (Roman Society of Natural Science)
Past Editor-in-Chief Italian Journal of Dermosurgery

Ultima modifica il Mercoledì, 21 Ottobre 2026 09:55
Vota questo articolo
(0 Voti)

Lascia un commento

Assicurati di aver digitato tutte le informazioni richieste, evidenziate da un asterisco (*). Non è consentito codice HTML.

 

Scienzaonline con sottotitolo Sciencenew  - Periodico
Autorizzazioni del Tribunale di Roma – diffusioni:
telematica quotidiana 229/2006 del 08/06/2006
mensile per mezzo stampa 293/2003 del 07/07/2003
Scienceonline, Autorizzazione del Tribunale di Roma 228/2006 del 29/05/06
Pubblicato a Roma – Via A. De Viti de Marco, 50 – Direttore Responsabile Guido Donati

Photo Gallery